Last reviewed · How we verify
Metronidazole 250 (7 days)
Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.
Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material. Used for Anaerobic bacterial infections, Trichomoniasis, Giardiasis.
At a glance
| Generic name | Metronidazole 250 (7 days) |
|---|---|
| Sponsor | University of Guarulhos |
| Drug class | Nitroimidazole antimicrobial |
| Target | Bacterial and parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a prodrug that is activated by anaerobic organisms and parasites to form reactive intermediates that bind to and cleave DNA, preventing replication and transcription. It is effective against anaerobic bacteria and certain protozoan parasites. The drug is bactericidal and antiprotozoal, making it useful for infections caused by these organisms.
Approved indications
- Anaerobic bacterial infections
- Trichomoniasis
- Amebiasis
- Giardiasis
- Bacterial vaginosis
- Clostridioides difficile infection
- Anaerobic abdominal and pelvic infections
Common side effects
- Metallic taste
- Nausea
- Headache
- Diarrhea
- Peripheral neuropathy
- Darkened urine
Key clinical trials
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Mechanisms and Treatment Response of Aggressive Periodontitis in Children (NA)
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (PHASE3)
- Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery (NA)
- Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome (PHASE4)
- Metronidazole as an Adjunct of Non- Surgical Treatment of Peri-implantitis (PHASE4)
- Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi) (NA)
- Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 250 (7 days) CI brief — competitive landscape report
- Metronidazole 250 (7 days) updates RSS · CI watch RSS
- University of Guarulhos portfolio CI